Why the study?
Does initiation on non-recommended antihypertensive therapy or fixed-dose combinations increase treatment discontinuation in patients starting antihypertensive therapy?
Population
55,937 persons initiating antihypertensive therapy in Australia
Comparison
Initiation on non-recommended monotherapy or… vs Initiation on recommended monotherapy
Design
Cohort
Follow-up
1 year
Authors
Loading...
Initiation on FDCs or non-recommended antihypertensives was associated with higher discontinuation; leaves open whether guideline-concordant monotherapy improves persistence.
Does initiation on non-recommended antihypertensive therapy or fixed-dose combinations increase treatment discontinuation in patients starting antihypertensive therapy?
Initiating antihypertensive therapy with fixed-dose combinations or non-recommended monotherapy is associated with higher rates of treatment discontinuation in the first year compared to recommended low-dose monotherapy.
Schaffer et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: